RECRUITING

A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma

Conditions

Metastatic Appendiceal Adenocarcinoma Intraperitoneal Paclitaxel

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

To find the recommended dose of the drug paclitaxel that can be given intraperitoneally (given directly into the abdominal cavity) to participants with metastatic appendiceal adenocarcinoma.

Official Title

A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma

Quick Facts

Study Start:2024-01-30

Study Completion:2028-01-02

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06207305

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Age 18 years and above. There will be no upper age restriction 2. ECOG performance status ≤ 2 3. Participants must have histologically confirmed diagnosis of unresectable locally metastatic appendiceal adenocarcinoma 4. Metastatic disease in the peritoneal cavity and not a candidate for cytoreductive surgery 5. Participants must have adequate organ and marrow function as defined below: 6. For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated 7. Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load 8. Participants with metastases outside the peritoneal cavity are not eligible for enrollment 9. Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial 10. The effects of PTX on the developing human fetus are unknown. For this reason, and because Taxane agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following: 1. Postmenopausal (no menses in greater than or equal to 12 consecutive months) 2. History of hysterectomy or bilateral salpingo-oophorectomy 3. Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy) 4. History of bilateral tubal ligation or another surgical sterilization procedure Approved methods of birth control are as follows: Hormonal contraception (i.e., birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. 11. Ability to understand and the willingness to sign a written informed consent document	1. Active infection such as pneumonia or wound infections that would preclude protocol therapy 2. Participants with unstable angina or New York Heart Association (NYHA) Grade II or greater congestive heart failure 3. Participants deemed unable to comply with study and/or follow-up procedures (i.e., cognitive impairment) 4. Participants with a known hypersensitivity to protocol systemic chemotherapy that was life-threatening, required hospitalization or prolongation of existing hospitalization, or resulted in persistent or significant disability or incapacity 5. Previous surgery that would preclude safe diagnostic laparoscopy with port placement 6. Participants who have not recovered from adverse events (AE) due to prior anti-cancer therapy (i.e., have residual toxicities \> Grade 1) with the exception of alopecia 7. Participants who are receiving any other investigational agents 8. Participants with metastases outside the peritoneal cavity 9. History of allergic reactions attributed to compounds of similar chemical or biologic composition to PTX or other agents used in study 10. Participants with psychiatric illness/social situations that would limit compliance with study requirements Participants who are pregnant

Inclusion Criteria

Exclusion Criteria

1. Age 18 years and above. There will be no upper age restriction
2. ECOG performance status ≤ 2
3. Participants must have histologically confirmed diagnosis of unresectable locally metastatic appendiceal adenocarcinoma
4. Metastatic disease in the peritoneal cavity and not a candidate for cytoreductive surgery
5. Participants must have adequate organ and marrow function as defined below:
6. For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
7. Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
8. Participants with metastases outside the peritoneal cavity are not eligible for enrollment
9. Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
10. The effects of PTX on the developing human fetus are unknown. For this reason, and because Taxane agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:
1. Postmenopausal (no menses in greater than or equal to 12 consecutive months)
2. History of hysterectomy or bilateral salpingo-oophorectomy
3. Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy)
4. History of bilateral tubal ligation or another surgical sterilization procedure Approved methods of birth control are as follows: Hormonal contraception (i.e., birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
11. Ability to understand and the willingness to sign a written informed consent document

1. Active infection such as pneumonia or wound infections that would preclude protocol therapy
2. Participants with unstable angina or New York Heart Association (NYHA) Grade II or greater congestive heart failure
3. Participants deemed unable to comply with study and/or follow-up procedures (i.e., cognitive impairment)
4. Participants with a known hypersensitivity to protocol systemic chemotherapy that was life-threatening, required hospitalization or prolongation of existing hospitalization, or resulted in persistent or significant disability or incapacity
5. Previous surgery that would preclude safe diagnostic laparoscopy with port placement
6. Participants who have not recovered from adverse events (AE) due to prior anti-cancer therapy (i.e., have residual toxicities \> Grade 1) with the exception of alopecia
7. Participants who are receiving any other investigational agents
8. Participants with metastases outside the peritoneal cavity
9. History of allergic reactions attributed to compounds of similar chemical or biologic composition to PTX or other agents used in study
10. Participants with psychiatric illness/social situations that would limit compliance with study requirements Participants who are pregnant

Contacts and Locations

Study Contact

Beth Helmink, MD

CONTACT

(832) 696-5784

bhelmink@mdanderson.org

Principal Investigator

Beth Helmink, MD

PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Study Locations (Sites)

MD Anderson Cancer Center

Houston, Texas, 77303

United States

Collaborators and Investigators

Sponsor: M.D. Anderson Cancer Center

Beth Helmink, MD, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-01-30

Study Completion Date2028-01-02

Study Record Updates

Study Start Date2024-01-30

Study Completion Date2028-01-02

Terms related to this study

Additional Relevant MeSH Terms

Metastatic Appendiceal Adenocarcinoma
Intraperitoneal Paclitaxel